Development of allogeneic HSC-engineered iNKT cells for off-the-shelf cancer immunotherapy.

doi:10.1016/j.xcrm.2021.100449

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Development of allogeneic HSC-engineered iNKT cells for off-the-shelf cancer immunotherapy.

Cell reports. Medicine - 16 Nov 2021

Li Yan-Ruide, Zhou Yang, Kim Yu Jeong, Zhu Yanni, Ma Feiyang, Yu Jiaji, Wang Yu-Chen, Chen Xianhui, Li Zhe, Zeng Samuel, Wang Xi, Lee Derek, Ku Josh, Tsao Tasha, Hardoy Christian, Huang Jie, Cheng Donghui, Montel-Hagen Amélie, Seet Christopher S, Crooks Gay M, Larson Sarah M, Sasine Joshua P, Wang Xiaoyan, Pellegrini Matteo, Ribas Antoni, Kohn Donald B, Witte Owen, Wang Pin, Yang Lili

Abstract excerpt

Cell-based immunotherapy has become the new-generation cancer medicine, and "off-the-shelf" cell products that can be manufactured at large scale and distributed readily to treat patients are necessary. Invariant natural killer T (iNKT) cells are ideal cell carriers for developing allogeneic cell therapy because they are powerful immune cells targeting cancers without graft-versus-host disease (GvHD) risk....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hematopoietic Stem Cells

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to HLA Antigens

Share to Immunotherapy

Share to Mice, Inbred NOD

Share to Mice, SCID

Share to Natural Killer T-Cells

Share to Receptors, Chimeric Antigen

Share to Transcriptome

Source

Open in PubMed Open full text

Identifiers

PMID: 34841295
DOI: 10.1016/j.xcrm.2021.100449
PMCID: PMC8607011

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development of allogeneic HSC-engineered iNKT cells for off-the-shelf cancer immunotherapy.PMID 34841295Read ↗

Engineering allorejection-resistant CAR-NKT cells from hematopoietic stem cells for off-the-shelf cancer immunotherapySemantic proximity Read ↗

Generation of dual-attribute iTNK cells from hPSCs for cancer immunotherapySemantic proximity Read ↗

Universal cell donor lines: A review of the current researchSemantic proximity Read ↗

Allogeneic CAR-T Cells: Engineering Around Host ImmunitySemantic proximity Read ↗

From induced pluripotent stem cell (iPSC) to universal immune cells: literature review of advances in a new generation of tumor therapiesSemantic proximity Read ↗

Hypoimmunogenic CD19 CAR-NK cells derived from embryonic stem cells suppress the progression of human B-cell malignancies in xenograft animalsSemantic proximity Read ↗

Pluripotent stem cell-derived siTNK cells attack tumors via a synthetic CD8-CD28-TCR complexSemantic proximity Read ↗

Adoptive immunotherapy with genetically modified lymphocytes in allogeneic stem cell transplantationSemantic proximity Read ↗

Induced Pluripotent Stem Cell (iPSC)–Derived Lymphocytes for Adoptive Cell Immunotherapy: Recent Advances and ChallengesSemantic proximity Read ↗

Advances in Allogeneic Cancer Cell Therapy and Future Perspectives on “Off-the-Shelf” T Cell Therapy Using iPSC Technology and Gene EditingSemantic proximity Read ↗

Multiplexed iPSC platform for advanced NK cell immunotherapiesSemantic proximity Read ↗

Genetic engineering strategies to enhance antitumor reactivity and reduce alloreactivity for allogeneic cell-based cancer therapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.